In a report released yesterday, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Zynex (ZYXI – Research Report), with a price target of $15.00. The company’s shares closed yesterday at $10.97.
According to TipRanks, Singh Chadha is an analyst with an average return of -0.7% and a 38.38% success rate. Singh Chadha covers the Healthcare sector, focusing on stocks such as Boston Scientific, Johnson & Johnson, and Zynex.
Currently, the analyst consensus on Zynex is a Moderate Buy with an average price target of $18.00, a 64.08% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $21.00 price target.
ZYXI market cap is currently $360.6M and has a P/E ratio of 41.88.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zynex (ZYXI) Company Description:
Zynex, Inc. engages in the design, manufacture, and marketing of medical devices. It sells electrotherapy medical devices used for pain management and rehabilitation. The company also develops a new blood volume monitor for use in hospitals and surgery centers. Zynex was founded by Thomas Sandgaard in 1996 and is headquartered in Englewood, CO.
Read More on ZYXI:
